Home | Meeting coverage | ECCO 2021

Spotlight Discussion – Therapy highlights & new horizons

ECCO 2021

S. Danese, S. Vermeire, S. Schreiber, A. Dignaß, F. Magro, J. Lindsay, P. Sewerin

Novel agents: Do we need new drugs or just...

ECCO 2021

S. Vermeire, F. Magro, A. Dignaß, S. Danese, P. Irving, S. Schreiber, P. Sewerin

Comparing the different modes of action in IBD:...

ECCO 2021

A. Dignaß, F. Magro, J. Lindsay, P. Eder, P. Sewerin

IL23 inhibiton: Efficacy & Safety Updates

ECCO 2021

A. Dignaß, S. Vermeire, F. Magro, J. Lindsay, P. Eder, P. Irving, S. Schreiber, P. Sewerin

Role of JAKi in IBD: What’s new in 2021?

Spotlight Discussion – Therapy concepts, diagnostics/imaging

ECCO 2021

A. Dignaß, D. Laharie, F. Gomollón, M. Fantini, S. Schreiber, T. Kucharzik, P. Sewerin

Therapeutic algorithms: How to define? Transfering...

ECCO 2021

A. Dignaß, D. Laharie, F. Gomollón, M. Fantini, T. Kucharzik, P. Sewerin

What are the therapeutic goals in IBD? Clinical goals...

ECCO 2021

A. Dignaß, D. Laharie, F. Gomollón, M. Fantini, T. Kucharzik, P. Sewerin

Artificial Intelligence in IBD ... Even today a part of...

ECCO 2021

A. Dignaß, D. Laharie, F. Gomollón, T. Kucharzik, P. Sewerin

Imaging: routine care vs. clinical trial setting? The...

Artificial Intelligence – ENG

ECCO 2021

David Laharie, MD

Classification through AI is coming!

ECCO 2021

Fernando Gomollón, MD, PhD

AI is coming!

ECCO 2021

Axel Dignaß, MD, PhD

AI - Has artificial intelligence reached IBD

ECCO 2021

Massimo Claudio Fantini, MD, PhD

AI: The new frontier in endoscopy interpretation

Artificial Intelligence – FRA/ESP/ITA/GER

ECCO 2021

David Laharie, MD

L'intelligence artificielle arrive dans la RCH !

ECCO 2021

Fernando Gomollón, MD, PhD

AI está llegando!

ECCO 2021

Axel Dignaß, MD, PhD

Künstliche Intelligenz hilfreich bei Auswertung...

ECCO 2021

Massimo Claudio Fantini, MD, PhD

Intelligenza artificiale: la nuova frontiera in...

Therapy concepts – ENG

ECCO 2021

Piotr Eder, MD, Phd

Need for early resection in Crohn's disease is not...

ECCO 2021

Fernando Magro, MD, PhD

More JAK inhibitors - same questions!

ECCO 2021

Fernando Magro, MD, PhD

SEAVUE: From efficacy to pharmacoeconomic perspectives

ECCO 2021

Piotr Eder, MD, Phd

The SEAVUE Trial - will it help us to guide and...

ECCO 2021

David Laharie, MD

Which treatment for acute/severe UC after steroid...

ECCO 2021

James Lindsay, PhD

SEAVUE: no difference in remission between ustekinumab...

ECCO 2021

Peter Irving, MD

SAEVUE: The 1st biologic head-to-head trial in Crohn's...

ECCO 2021

Silvio Danese, MD, PhD

SEAVUE: Early intervention leads to great remission;...

ECCO 2021

Massimo Claudio Fantini, MD, PhD

SEAVUE - Head-to-head comparison: Applicable for daily...

ECCO 2021

Axel Dignaß, MD, PhD

New Therapeutic Strategies: STARDUST treat-to-target...

Therapy concepts – FRA/ITA/GER/POL

ECCO 2021

Piotr Eder, MD, Phd

Leczenie chirurgiczne na bardzo wczesnym etapie choroby...

ECCO 2021

Piotr Eder, MD, Phd

Badanie SEAVUE - czy pomoże nam pozycjonować leki...

ECCO 2021

David Laharie, MD

Enfin un seuil avec l'UCEIS !

ECCO 2021

Silvio Danese, MD, PhD

SEAVUE: Early intervention leads to great remission;...

ECCO 2021

Massimo Claudio Fantini, MD, PhD

Adalimumab vs Ustekinumab: dai risultati di confronto...

ECCO 2021

Axel Dignaß, MD, PhD

Welche Therapiestrategie für welches Therapieziel?

Diagnostics and Prediction – ENG

ECCO 2021

Stefan Schreiber, MD

Liquid biopsy opens exciting window for biomarker...

ECCO 2021

Fernando Magro, MD, PhD

VARSITY: Epithelial neutrophils are very important...

ECCO 2021

Fernando Magro, MD, PhD

Symsptoms and signs assocation - the value of histology

ECCO 2021

Séverine Vermeire, MD

Liquid biopsy as a novel non-invasive biomarker in IBD

ECCO 2021

David Laharie, MD

Towards UCEIS cutoff in UC

ECCO 2021

Johan Burisch, MD

Hot topic: Intestinational ultrasound for disease...

ECCO 2021

Torsten Kucharzik, MD

PREdiCCt: Predictive factors associated with fatigue in...

ECCO 2021

Torsten Kucharzik, MD

Predictive value of Milan Ultrasound in UC

Diagnostics and Prediction – FRA/DEN/GER

ECCO 2021

David Laharie, MD

Quel traitement d'entretien en cas de colite aiguë...

ECCO 2021

Johan Burisch, MD

Hot topic: Tarmultralyd til monitorering af Crohn's...

ECCO 2021

Torsten Kucharzik, MD

PREdiCCt: Fatigue assoziierte prädiktive Faktoren

ECCO 2021

Torsten Kucharzik, MD

Prädiktiver Wert des Darmultraschalls bei UC

Therapy - new drugs – ENG

ECCO 2021

Stefan Schreiber, MD

VIBRATO: Ritlecitinib and brepocitinib both effective....

ECCO 2021

Stefan Schreiber, MD

ADVANCE and MOTIVATE: Risankizumab with fast induction...

ECCO 2021

Stefan Schreiber, MD

SELECTION updates: no apparent safety concerns for...

ECCO 2021

James Lindsay, PhD

IL-23 inhibition with risankizumab effective for...

ECCO 2021

James Lindsay, PhD

Upadacitinib significantly effective in UC...

ECCO 2021

Severine Vermeire, MD

Results form phase 3 induction studies with...

ECCO 2021

Peter Irving, MD

Upadacitinib: Impressive induction data in Ulcerative...

ECCO 2021

Silvio Danese, MD, PhD

New drugs with signifiicant efficacy: ritlecitinib,...

ECCO 2021

Axel Dignaß, MD, PhD

IL-12/23 Blockade: Mechanism of action

ECCO 2021

Axel Dignaß, MD, PhD

New Therapeutic Treatments in IBD: JAKi

Therapy - new drugs – BEL/ITA/GER

ECCO 2021

Stefan Schreiber, MD

Anti-IL-23 Antikörper könnten potentielle Game-changer...

ECCO 2021

Stefan Schreiber, MD

Ritlecitinib und Brepocitinib: Neue Targets der...

ECCO 2021

Severine Vermeire, MD

Resultaten van de fase 3 inductie studies met...

ECCO 2021

Silvio Danese, MD, PhD

New drugs with signifiicant efficacy: ritlecitinib,...

ECCO 2021

Axel Dignaß, MD, PhD

Neue Aspekte zu IL-12 und IL-23-Antikörpern

ECCO 2021

Axel Dignaß, MD, PhD

Neue Daten zu JAK-Inhibitoren

COVID-19 – ENG

ECCO 2021

Piotr Eder, MD, PhD

Immune response to anti-SARS-CoV-2 vaccinations in...

ECCO 2021

Piotr Eder, MD, Phd

5-ASA - back from the other side? New COVID-19 safety...

ECCO 2021

Peter Irving, MD

Providing CLARITY on COVID-19 in IBD

COVID-19 - POL

ECCO 2021

Piotr Eder, MD, Phd

Odpowiedź immunologiczna na szczepienia przeciw...

ECCO 2021

Piotr Eder, MD, Phd

5-ASA - powrót z zaświatów? Nowe dane z badania...

New drugs in IBD – ENG

ECCO 2021

Fernando Gomollón, MD, PhD

Wide spectrum of treatments for IBD

New Drugs in IBD – ESP

ECCO 2021

Fernando Gomollón, MD, PhD

Espectro de tratamientos amplio para IBD?

Varia – ENG

ECCO 2021

Stefan Schreiber, MD

CRAFT UC: Diet more effective than FMT? We need more...

ECCO 2021

Fernando Gomollón, MD, PhD

My perspective on ECCO2021

ECCO 2021

Severine Vermeire, MD

Fecal transplantation or diet for Ulcerative Colitis?

ECCO 2021

Johan Burisch, MD

Appendectomy for Ulcerative Colitis

ECCO 2021

Johan Burisch, MD

Increasing prevalence of IBD in Brazil

ECCO 2021

Torsten Kucharzik, MD

Update ECCO-Guideline on Vaccination and Vaccination...

Varia – ESP/GER/DEN/BEL

ECCO 2021

Stefan Schreiber, MD

Konditionierte Diät ist der FMT bei CU überlegen

ECCO 2021

Fernando Gomollón, MD, PhD

El ECCO 2021 desde mi punto de vista

ECCO 2021

Severine Vermeire, MD

Stoelgangstransplantatie of dieet voor colitis ulcera?

ECCO 2021

Johan Burisch, MD

Appendektomi ved patienter med colitis ulcerosa

ECCO 2021

Johan Burisch, MD

Stigende forekomst af IBD i Brasilien

ECCO 2021

Torsten Kucharzik, MD

Neue ECCO-Leitlinie zu Infektionen und Impstrategie